Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Health Canada Approves PLEGRIDY™ (peginterferon beta-1a) for Adults with Relapsing Remitting Multiple Sclerosis
Balance impairment in people with multiple sclerosis: Preliminary evidence for the Balance Evaluation Systems Test.
[The influence of locomotor treatment using robotic body-weight-supported treadmill training on rehabilitation outcome of patients suffering from neurological disorders].
Daclizumab high-yield process reduced the evolution of new gadolinium-enhancing lesions to T1 black holes in patients with relapsing-remitting multiple sclerosis.
Recombinant T cell receptor ligands: immunomodulatory, neuroprotective and neuroregenerative effects suggest application as therapy for multiple sclerosis.
Incidence of multiple sclerosis in the United Kingdom : findings from a population-based cohort.
Therapeutic effects of novel sphingosine-1-phosphate receptor agonist W-061 in murine DSS colitis.
Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis.
A gradient in cortical pathology in multiple sclerosis by in vivo quantitative 7 T imaging.
iPSC-derived neural precursors exert a neuroprotective role in immune-mediated demyelination via the secretion of LIF.
Glatiramer acetate and interferon-beta throughout gestation and postpartum in women with multiple sclerosis.
Durable pharmacological responses from the peptide drug ShK-186, a specific Kv1.3 channel inhibitor that suppresses T cell mediators of autoimmune disease.
Regional Susceptibility to TNF-α Induction of Murine Brain Inflammation via Classical IKK/NF-κB Signalling.
Identification of the LDL Receptor-Related Protein-1 Interactome in Central Nervous System myelin suggests a role in the clearance of necrotic cell debris.
Valproic acid ameliorates inflammation in experimental autoimmune encephalomyelitis rats.
Efficacy and safety of Privigen(®) in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study (the PRIMA study).
Teva Announces U.S. Supreme Court Will Hear Its Appeal on COPAXONE(R) Patent
Amiloride HCl
Pregnancy outcomes in female patients and partners of male patients in the teriflunomide clinical development program.
Increased PK11195 PET binding in the cortex of patients with MS correlates with disability.
Super-resolution imaging of aquaporin-4 orthogonal arrays of particles in cell membranes.
Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor.
Vitamin D-dependent rickets, HLA-DRB1, and the risk of multiple sclerosis.
Asymptomatic lung disease caused by Mycobacterium kansasii as an opportunistic infection in a patient treated with natalizumab for relapsing-remitting multiple sclerosis.
Comparing the biological impact of glatiramer acetate with the biological impact of a generic.

Pages